Genmab Stock Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 135B 20.3B 18.03B 16.82B 15.33B 28.91B 1,955B 29.18B 204B 79.05B 997B 76.23B 74.57B 3,204B | P/E 2026 * |
28.1x | P/E 2027 * | 20x |
|---|---|---|---|---|---|
| Enterprise Value | 154B 23.2B 20.6B 19.22B 17.52B 33.04B 2,234B 33.35B 233B 90.33B 1,139B 87.11B 85.22B 3,662B | EV / Sales 2026 * |
5.3x | EV / Sales 2027 * | 4.32x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 20.81B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -3.11% | -2.32% | +23.28% | +77.03% | 59.26B | |
| +0.89% | -0.77% | +5.80% | +32.89% | 47.14B | |
| -0.96% | -6.11% | +26.70% | +31.24% | 42.91B | |
| +0.36% | +3.39% | +350.59% | +646.53% | 44.13B | |
| -0.20% | -0.53% | +6.84% | +99.07% | 40.79B | |
| -0.54% | +2.93% | +9.50% | +50.41% | 30.77B | |
| -2.68% | +5.11% | +33.11% | +19.50% | 29.31B | |
| +2.33% | -8.58% | -24.55% | +340.08% | 23.71B | |
| Average | -0.01% | -0.64% | +53.40% | +154.55% | 43.6B | |
| Weighted average by Cap. | +0.21% | -0.40% | +58.36% | +145.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.07B 4.38B 3.89B 3.63B 3.3B 6.23B 421B 6.29B 43.88B 17.04B 215B 16.43B 16.07B 691B | 33.76B 5.08B 4.51B 4.21B 3.84B 7.24B 489B 7.31B 50.96B 19.79B 250B 19.08B 18.67B 802B |
| Net income | 4.98B 750M 666M 621M 566M 1.07B 72.24B 1.08B 7.52B 2.92B 36.84B 2.82B 2.76B 118B | 7.18B 1.08B 959M 895M 816M 1.54B 104B 1.55B 10.83B 4.21B 53.07B 4.06B 3.97B 171B |
| Net Debt | 19.25B 2.9B 2.57B 2.4B 2.19B 4.13B 279B 4.17B 29.06B 11.29B 142B 10.88B 10.65B 457B | 11.09B 1.67B 1.48B 1.38B 1.26B 2.38B 161B 2.4B 16.75B 6.5B 82.02B 6.27B 6.13B 264B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
